Concepts (162)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hematopoietic Stem Cell Transplantation | 9 | 2014 | 914 | 0.310 |
Why?
|
| Leukemia, Myeloid, Acute | 5 | 2021 | 802 | 0.250 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2021 | 1362 | 0.200 |
Why?
|
| Thiotepa | 7 | 2006 | 32 | 0.200 |
Why?
|
| Quinolones | 1 | 2021 | 57 | 0.190 |
Why?
|
| Maintenance Chemotherapy | 1 | 2021 | 84 | 0.190 |
Why?
|
| Lymphatic Irradiation | 2 | 2014 | 7 | 0.190 |
Why?
|
| Hodgkin Disease | 2 | 2014 | 169 | 0.170 |
Why?
|
| Thrombocytopenia | 1 | 2020 | 186 | 0.170 |
Why?
|
| Pharmaceutical Preparations | 1 | 2020 | 92 | 0.160 |
Why?
|
| Oligodendroglioma | 3 | 2006 | 45 | 0.160 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 7 | 2007 | 2525 | 0.140 |
Why?
|
| Hematopoietic Stem Cells | 2 | 2009 | 309 | 0.140 |
Why?
|
| Hematologic Neoplasms | 2 | 2009 | 354 | 0.110 |
Why?
|
| Mitoxantrone | 2 | 1990 | 68 | 0.110 |
Why?
|
| Brain Neoplasms | 3 | 2006 | 781 | 0.110 |
Why?
|
| Cyclophosphamide | 4 | 1990 | 303 | 0.110 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2014 | 143 | 0.100 |
Why?
|
| Positron-Emission Tomography | 1 | 2014 | 340 | 0.100 |
Why?
|
| Antineoplastic Agents | 3 | 2021 | 2337 | 0.100 |
Why?
|
| Antigens, CD34 | 2 | 2009 | 161 | 0.100 |
Why?
|
| Carmustine | 2 | 1990 | 70 | 0.090 |
Why?
|
| Survival Rate | 7 | 2021 | 1895 | 0.080 |
Why?
|
| Middle Aged | 19 | 2021 | 26347 | 0.080 |
Why?
|
| Melphalan | 1 | 1989 | 99 | 0.080 |
Why?
|
| Salvage Therapy | 2 | 2021 | 233 | 0.070 |
Why?
|
| Daptomycin | 1 | 2006 | 3 | 0.070 |
Why?
|
| Combined Modality Therapy | 6 | 2014 | 1709 | 0.060 |
Why?
|
| Vancomycin Resistance | 1 | 2006 | 18 | 0.060 |
Why?
|
| Enterococcus faecium | 1 | 2006 | 33 | 0.060 |
Why?
|
| Gram-Positive Bacterial Infections | 1 | 2006 | 50 | 0.060 |
Why?
|
| Female | 20 | 2021 | 46894 | 0.060 |
Why?
|
| Waldenstrom Macroglobulinemia | 1 | 2004 | 11 | 0.060 |
Why?
|
| Theophylline | 1 | 2004 | 34 | 0.060 |
Why?
|
| Stem Cell Transplantation | 1 | 2006 | 190 | 0.060 |
Why?
|
| Body Weight | 1 | 2006 | 455 | 0.060 |
Why?
|
| Aged | 13 | 2014 | 19424 | 0.060 |
Why?
|
| Male | 18 | 2021 | 42967 | 0.060 |
Why?
|
| Vasodilator Agents | 1 | 2004 | 145 | 0.060 |
Why?
|
| Adult | 15 | 2014 | 26953 | 0.050 |
Why?
|
| Prognosis | 4 | 2021 | 3813 | 0.050 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2004 | 160 | 0.050 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2003 | 134 | 0.050 |
Why?
|
| Transplantation, Autologous | 4 | 2014 | 351 | 0.050 |
Why?
|
| Humans | 24 | 2021 | 90640 | 0.050 |
Why?
|
| Recurrence | 3 | 2014 | 1162 | 0.050 |
Why?
|
| Etoposide | 3 | 2000 | 203 | 0.050 |
Why?
|
| Antibodies, Monoclonal | 2 | 2006 | 1397 | 0.050 |
Why?
|
| Survival Analysis | 4 | 2006 | 1500 | 0.040 |
Why?
|
| Transplantation, Homologous | 3 | 2009 | 1000 | 0.040 |
Why?
|
| Trastuzumab | 1 | 2020 | 77 | 0.040 |
Why?
|
| Treatment Outcome | 6 | 2014 | 8379 | 0.040 |
Why?
|
| Remission Induction | 2 | 2014 | 745 | 0.040 |
Why?
|
| Prospective Studies | 3 | 2021 | 4348 | 0.040 |
Why?
|
| Anti-Bacterial Agents | 1 | 2006 | 806 | 0.040 |
Why?
|
| B-Lymphocytes | 1 | 2004 | 741 | 0.040 |
Why?
|
| Follow-Up Studies | 3 | 2021 | 3698 | 0.040 |
Why?
|
| Procarbazine | 3 | 2006 | 38 | 0.040 |
Why?
|
| Lomustine | 3 | 2006 | 26 | 0.040 |
Why?
|
| Vincristine | 3 | 2006 | 108 | 0.040 |
Why?
|
| Antibodies | 1 | 2020 | 353 | 0.040 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 1999 | 112 | 0.040 |
Why?
|
| Breast Neoplasms | 2 | 1989 | 3020 | 0.040 |
Why?
|
| Apoptosis | 1 | 2004 | 1725 | 0.040 |
Why?
|
| Cell Count | 2 | 2009 | 200 | 0.040 |
Why?
|
| Disease-Free Survival | 3 | 2006 | 1170 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 9 | 2 | 1988 | 80 | 0.040 |
Why?
|
| Translocation, Genetic | 2 | 1988 | 264 | 0.030 |
Why?
|
| Neoplasm Staging | 2 | 2014 | 2019 | 0.030 |
Why?
|
| Adolescent | 4 | 2014 | 9354 | 0.030 |
Why?
|
| Aged, 80 and over | 4 | 2004 | 6816 | 0.030 |
Why?
|
| Bone Marrow Transplantation | 2 | 2000 | 286 | 0.030 |
Why?
|
| Alkylating Agents | 2 | 1990 | 32 | 0.030 |
Why?
|
| Cisplatin | 2 | 2000 | 599 | 0.020 |
Why?
|
| Neoplasms, Second Primary | 1 | 2014 | 240 | 0.020 |
Why?
|
| Young Adult | 2 | 2014 | 6426 | 0.020 |
Why?
|
| Infusions, Intravenous | 1 | 1990 | 419 | 0.020 |
Why?
|
| Calibration | 1 | 2009 | 104 | 0.020 |
Why?
|
| Bone Marrow | 1 | 1990 | 446 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 11 | 1 | 1988 | 106 | 0.020 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 1990 | 267 | 0.020 |
Why?
|
| Transplantation Conditioning | 1 | 2009 | 378 | 0.020 |
Why?
|
| Abelson murine leukemia virus | 1 | 1987 | 3 | 0.020 |
Why?
|
| Leukemia, Lymphoid | 1 | 1987 | 72 | 0.020 |
Why?
|
| Leukemia Virus, Murine | 1 | 1987 | 18 | 0.020 |
Why?
|
| Carcinoma, Small Cell | 1 | 1987 | 133 | 0.020 |
Why?
|
| Proto-Oncogenes | 1 | 1987 | 61 | 0.020 |
Why?
|
| Cell Survival | 1 | 1989 | 987 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 7 | 1 | 1987 | 79 | 0.020 |
Why?
|
| Leukemia, Hairy Cell | 1 | 1987 | 186 | 0.020 |
Why?
|
| Cecal Neoplasms | 1 | 2006 | 5 | 0.020 |
Why?
|
| Sigmoid Neoplasms | 1 | 2006 | 9 | 0.020 |
Why?
|
| Trisomy | 1 | 2006 | 54 | 0.020 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 1987 | 110 | 0.020 |
Why?
|
| Thinness | 1 | 2006 | 46 | 0.020 |
Why?
|
| Interferon Type I | 1 | 1987 | 187 | 0.020 |
Why?
|
| Siblings | 1 | 2006 | 106 | 0.020 |
Why?
|
| Organoplatinum Compounds | 1 | 2006 | 94 | 0.020 |
Why?
|
| Leucovorin | 1 | 2006 | 222 | 0.020 |
Why?
|
| Omentum | 1 | 2006 | 74 | 0.020 |
Why?
|
| Tissue and Organ Harvesting | 1 | 2006 | 79 | 0.020 |
Why?
|
| Leukemia | 1 | 1987 | 320 | 0.020 |
Why?
|
| Chromosome Deletion | 1 | 2006 | 227 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 1989 | 1935 | 0.020 |
Why?
|
| Neoplasms | 2 | 1990 | 3030 | 0.020 |
Why?
|
| Bone Marrow Diseases | 2 | 2000 | 40 | 0.020 |
Why?
|
| Overweight | 1 | 2006 | 118 | 0.020 |
Why?
|
| Bevacizumab | 1 | 2006 | 268 | 0.010 |
Why?
|
| bcl-2-Associated X Protein | 1 | 2004 | 46 | 0.010 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2004 | 78 | 0.010 |
Why?
|
| Lung Neoplasms | 2 | 1987 | 2370 | 0.010 |
Why?
|
| Peritoneal Neoplasms | 1 | 2006 | 181 | 0.010 |
Why?
|
| Fluorouracil | 1 | 2006 | 548 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 2006 | 898 | 0.010 |
Why?
|
| Rituximab | 1 | 2004 | 120 | 0.010 |
Why?
|
| Antigens, CD | 1 | 2006 | 467 | 0.010 |
Why?
|
| Graft vs Host Disease | 1 | 2006 | 362 | 0.010 |
Why?
|
| Retrospective Studies | 2 | 2009 | 9330 | 0.010 |
Why?
|
| Cyclic AMP | 1 | 2004 | 279 | 0.010 |
Why?
|
| Probability | 1 | 2004 | 357 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2004 | 194 | 0.010 |
Why?
|
| Karyotyping | 3 | 1988 | 252 | 0.010 |
Why?
|
| Administration, Oral | 1 | 2004 | 671 | 0.010 |
Why?
|
| Graft Survival | 1 | 2006 | 913 | 0.010 |
Why?
|
| Age Factors | 1 | 2006 | 1871 | 0.010 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2004 | 665 | 0.010 |
Why?
|
| Karnofsky Performance Status | 1 | 2000 | 39 | 0.010 |
Why?
|
| Cachexia | 1 | 2000 | 13 | 0.010 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2006 | 962 | 0.010 |
Why?
|
| Treatment Failure | 1 | 2000 | 282 | 0.010 |
Why?
|
| Ovarian Neoplasms | 1 | 2006 | 776 | 0.010 |
Why?
|
| Drug Evaluation | 2 | 1990 | 137 | 0.010 |
Why?
|
| Brain Diseases | 1 | 2000 | 188 | 0.010 |
Why?
|
| Adenocarcinoma | 1 | 2006 | 1182 | 0.010 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 1987 | 1129 | 0.010 |
Why?
|
| Cerebral Hemorrhage | 1 | 2000 | 342 | 0.010 |
Why?
|
| Cost-Benefit Analysis | 1 | 1999 | 474 | 0.010 |
Why?
|
| Risk Factors | 1 | 2006 | 5583 | 0.010 |
Why?
|
| Disease Progression | 1 | 2000 | 1486 | 0.010 |
Why?
|
| Actuarial Analysis | 1 | 1990 | 66 | 0.010 |
Why?
|
| Preoperative Care | 1 | 1990 | 400 | 0.000 |
Why?
|
| Chromosome Banding | 1 | 1988 | 73 | 0.000 |
Why?
|
| Blood Cell Count | 1 | 1987 | 80 | 0.000 |
Why?
|
| Bone Marrow Examination | 1 | 1987 | 47 | 0.000 |
Why?
|
| Splenectomy | 1 | 1987 | 82 | 0.000 |
Why?
|
| Alkaline Phosphatase | 1 | 1987 | 132 | 0.000 |
Why?
|
| Nucleic Acid Hybridization | 1 | 1987 | 243 | 0.000 |
Why?
|
| Genes, Viral | 1 | 1987 | 117 | 0.000 |
Why?
|
| Genetic Markers | 1 | 1988 | 477 | 0.000 |
Why?
|
| Hematologic Diseases | 1 | 1987 | 78 | 0.000 |
Why?
|
| Opportunistic Infections | 1 | 1987 | 60 | 0.000 |
Why?
|
| Random Allocation | 1 | 1987 | 327 | 0.000 |
Why?
|
| Chicago | 1 | 1990 | 1441 | 0.000 |
Why?
|
| Acute Disease | 1 | 1987 | 854 | 0.000 |
Why?
|
| Neutrophils | 1 | 1987 | 313 | 0.000 |
Why?
|
| Recombinant Proteins | 1 | 1987 | 1015 | 0.000 |
Why?
|
| Neoplasm Proteins | 1 | 1987 | 538 | 0.000 |
Why?
|
| Cell Line | 1 | 1987 | 2505 | 0.000 |
Why?
|
| Heart Failure | 1 | 1990 | 1270 | 0.000 |
Why?
|
| Child, Preschool | 1 | 1988 | 3767 | 0.000 |
Why?
|
| T-Lymphocytes | 1 | 1987 | 1229 | 0.000 |
Why?
|
| Child | 1 | 1987 | 7219 | 0.000 |
Why?
|